{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:23:55Z","timestamp":1762251835790},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T00:00:00Z","timestamp":1332806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Zoledronic acid (ZOL), an intravenous bisphosphonate, has been shown to reduce and delay the incidence of skeletal\u2010related events (SREs) in multiple myeloma (MM) patients with bone disease. A retrospective claims\u2010based analysis was conducted that used two distinct US managed care databases to examine the relationship between persistency with ZOL and clinical benefit. Patients &gt;18 years, diagnosed with MM, and with at least one claim for ZOL (or a claim for malignant bone disease and ZOL initiation within 30 days) between 1\/1\/2001 and 12\/31\/2006 were included. Patients were evaluated for incidence of SREs and for mortality. Treatment persistency was defined as the absence of a &gt;45 day gap between ZOL administrations. Of 1,655 patients in this analysis, 1,060 received ZOL and 595 received no intravenous bisphosphonate therapy. Compared with patients not receiving bisphosphonate therapy, ZOL\u2010treated patients had lower incidences of SREs (<jats:italic>P<\/jats:italic> &lt; 0.0001) and death (<jats:italic>P<\/jats:italic> = 0.0001). Longer persistency with ZOL was associated with lower risks of SREs (<jats:italic>P<\/jats:italic> = 0.001), fracture (<jats:italic>P<\/jats:italic> = 0.003), and death (<jats:italic>P<\/jats:italic> = 0.002) versus shorter persistency. Patients who were persistent with ZOL for \u22651.5 years had an incidence of 15.0 SREs and 6.2 fractures per 100 person\u2010years. Patients who were persistent for 31\u201390 days had an incidence of 24.6 SREs and 14.0 fractures per 100 person\u2010years, and patients not receiving intravenous bisphosphonates had an incidence of 32.2 SREs and 16.9 fractures per 100 person\u2010years. These data from a real\u2010world setting indicate that among MM patients, longer persistency with ZOL was associated with a lower risk of SREs and fracture. Am. J. Hematol. 87:490\u2013495, 2012. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23164","type":"journal-article","created":{"date-parts":[[2012,2,24]],"date-time":"2012-02-24T12:41:41Z","timestamp":1330087301000},"page":"490-495","source":"Crossref","is-referenced-by-count":15,"title":["Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma"],"prefix":"10.1002","volume":"87","author":[{"given":"Henry J.","family":"Henk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Teitelbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ricardo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyin","family":"Kaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2007.08.003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-suppl_1-20"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.037"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22991"},{"key":"e_1_2_6_6_2","first-page":"377","article-title":"Assessment and treatment of patients with malignant spinal cord compression","volume":"2","author":"Abrahm JL","year":"2004","journal-title":"J Support Oncol"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2007.n.003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.10.006"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi235"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(11)70004-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93075-X"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02851.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00567.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8 <1661::AID-CNCR16>3.0.CO;2-Y"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90037-H"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-6-687"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90452-B"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0688"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23783"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"e_1_2_6_22_2","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/jco.2011.29.15_suppl.8011","article-title":"Are there benefits to long\u2010term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX trial","volume":"29","author":"Davies FE","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.8.1047"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.03.007"},{"key":"e_1_2_6_25_2","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma Version 1.2012. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."},{"key":"e_1_2_6_26_2","volume-title":"Xgeva\u2122 (denosumab) injection [package insert]","year":"2010"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"e_1_2_6_28_2","doi-asserted-by":"crossref","unstructured":"BoydK.Does zoledronic acid reduce skeletal\u2010related events and improve progression\u2010free survival in patients with multiple myelopma with or without bone disease? MRC Myeloma IX study results. Presented at: 47th Annual Meeting of American Society of Clinical Oncology; June 3\u20137 2011; Chicago IL. Abstract 8010.","DOI":"10.1200\/jco.2011.29.15_suppl.8010"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-10-842"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70157-7"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02698044"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24758"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","unstructured":"MorganGJ DaviesFE GregoryWM et al.Defining the biological subgroup of multiple myeloma patients which benefits maximally from the overall survival benefit associated with treatment with zoledronic acid. Presented at: 47th Annual Meeting of American Society of Clinical Oncology; June 3\u20137 2011; Chicago IL. Abstract8083.","DOI":"10.1200\/jco.2011.29.15_suppl.8083"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V108.11.3589.3589","article-title":"Zoledronic acid may improve survival compared to pamidronate in patients with MM and high BALP levels: Univariate and multivariate models of hazard ratios","volume":"108","author":"Berenson JR","year":"2006","journal-title":"Blood"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2010.483508"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23164","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:35:05Z","timestamp":1700573705000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,27]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1002\/ajh.23164"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23164","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,27]]}}}